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Abstract
Background: Neutrophil dysfunction plays a key role in the development of diseases characterized by inflammation
and angiogenesis. Here, we studied the systemic expression of neutrophil markers reflecting activation, adhesion, and
resolution of inflammation in patients with neovascular age-related macular degeneration (AMD).
Results: This was a prospective case-control study of patients with neovascular AMD and age-matched healthy control
individuals. Patients were recruited from an outpatient program, and control individuals were recruited amongst
patients’ relatives. Current smokers and individuals with either active immune-disease or ongoing cancer were
not included, as these factors are known to affect neutrophil function. Fresh-drawn venous blood was processed
for flow cytometric analysis of neutrophil markers. We determined percentages of positive cells and compared
expression levels using fluorescence intensity measures. We found conditional differences on marker expression
between patients with neovascular AMD (n = 29) and controls (n = 28): no differences were found when looking
broadly, but several differences emerged when focusing on non-smokers. Here, patients with neovascular AMD
had increased expression of the activity marker cluster of differentiation (CD) 66b (P = 0.003; Mann-Whitney U
test), decreased expression of adhesion marker CD162 (P = 0.044; Mann-Whitney U test), and lower expression of
the resolution of inflammation marker C-X-C chemokine receptor 2 (P = 0.044; Mann-Whitney U test).
Conclusions: We present novel evidence suggesting that the activity of circulating neutrophils, sensitive to
smoking, may differ in patients with neovascular AMD.
Keywords: Neutrophils, Age-related macular degeneration, Choroidal neovascularization, Flow cytometry, Inflammation
Background
Age-related macular degeneration (AMD) is a chronic
progressive disease of the aged macula [1]. In the early
stages, the disease is clinically characterized by drusen,
which are yellow deposits between Bruch’s membrane
and the retinal pigment epithelium [1]. The late stages
of AMD are characterized by localized atrophy of the
retina or by choroidal neovascularizations (CNV) [1].
The latter instance is described as neovascular AMD
due to its key feature where newly formed vessels of the
choroid penetrate through Bruch’s membrane into the
subretinal space [1]. Consequently, fluid and blood leak
into the retina, irreversibly impairing vision and visual
function [2]. The treatment is only able to keep vision at
a stable level for some years, and neovascular AMD still
remains the most common reason for irreversible vision
loss in the developed world [2–4].
The pathogenesis of neovascular AMD remains in-
completely understood, but ageing and dysfunction of
the immune system are believed to play a key role for the
disease to develop in an aged macula [5–7]. A current de-
veloping area of interest is how neutrophils play a role in
disease development. This is particularly interesting since
aging is the highest risk factor of developing neovascular
AMD and aged neutrophils are characterized by changed
surface expression and activity [5–8]. Studies have
found a higher neutrophil/lymphocyte ratio in patients
with neovascular AMD [9–11], and studies of donor eyes
have shown infiltrating lipocalin-2-positive neutrophils at
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significantly higher levels in retina and the choroid in both
early and late stages of AMD [12]. Lipocalin-2 is a protein
expressed in neutrophils, and levels of intravitreal
lipocalin-2 are significantly elevated in eyes with neovas-
cular AMD [13].
Neutrophils are the most prominent granulocytes and
are part of the innate immune system practicing gran-
ulocyte release and phagocytosis [14]. Following stimuli,
the activated neutrophils adhere to the endothelial cells
in the area of inflammation and migrate their way to the
site of injury and infection. Neutrophilic action is medi-
ated through an effective combination of cytotoxic gran-
ules, antimicrobial peptides, and neutrophil extracellular
traps [15]. Circulating neutrophils contains myeloperoxi-
dase (MPO), which can form a hypochlourous acid that
is an efficient killer of pathogens. In Parkinson’s disease
and Alzheimer’s disease, MPO is redistributed into the
extracellular space where it mediates tissue damage
[16, 17], which is a mechanism suspected of contributing
to the pathogenesis of AMD. Accumulated MPO is a two-
edged sword: it may be beneficial by clearing toxic retinal
lipofuscin deposits, but may be harmful by causing lyso-
somal stress that results in cell death [18].
Several chemokines are suggested to play a role in
recruiting monocytes/macrophages and neutrophils result-
ing in the formation of CNVs [19]. Zhou et al. studied
laser-induced CNV on mice and found that neutrophils in-
filtrate the retinal tissue from the first day after stimulation
and that neutrophil-depleted mice had significantly smaller
CNV-response. [20] Lavalette et al. found that neutrophils
infiltrated the choroid 10 h after laser stimulation express-
ing the proangionetic interleukin 1β [21]. Taken together,
these findings support the theory that neutrophils may play
an important part in the early CNV-response. In humans,
we previously described that systemic levels of neutrophils
correlate with CNV-lesion size in patients with neovascular
AMD [22], which further supports a role for neutrophils in
CNV-development in AMD.
Based on these findings, we hypothesized that systemic
neutrophil expression and properties could be altered in
patients with wet AMD. To investigate this further, we
selected markers of interest representing key steps of
neutrophil activity: activation, adhesion, and inflam-
mation [23]. Neutrophil migration is a process, which
involves activation following interaction between ad-
hesion molecules on the neutrophils and their ligands
on the endothelial cells. Cluster of differentiation (CD)
63 and CD66b are activation-molecules expressed on
the surface of neutrophils after appropriate stimulation
[24, 25]. CD162 (P-selectin glycoprotein ligand-1) and
CD62L (P-selectin) are mediators of the first step of roll-
ing, after which integrin molecules CD11a (lymphocyte
function-associated antigen-1) and CD11b (macrophage
associated antigen-1) participate [23, 24, 26]. The process
of transmigration through the endothelial layer is medi-
ated by CD54 and CD31 (platelet endothelial cell adhesion
molecule-1) [27]. The degree of inflammatory activity of
neutrophils can be studied by measuring the expression
level of several markers. One such marker is the
interleukin-1-receptor-2 (IL1-R2), which is the receptor of
the highly proinflammatory cytokine interleukin-1 [28]. C-
X-C chemokine receptor 2 (CXCR2) is also important in
acute and chronic inflammation and is mainly regulated
by interleukin-8 [29]. C-C chemokine receptor 5 (CCR5)
is involved in resolution of inflammation [30]. The Duffy
antigen receptor for chemokines (DARC) is suggested to
play a role in inflammation since DARC seems to bind
a large number of chemokines whereby it might have a
protective role in preventing chemokine activation of
neutrophils and inflammation [31].
In this study, we wished to study alterations of the in-
nate immune system in neovascular AMD. We sampled
blood from patients with neovascular AMD and compared
them to that of aged-matched healthy control individuals.
We did not include any participants who were actively
smoking. Tobacco triggers acute inflammation mediated
via Toll-like-receptors [32] and modulates the expression of
pro-inflammatory cytokines and chemokines [33]. Also, to-
bacco smoking increases the risk of AMD significantly. The
increase in risk is most pronounced in current smokers,
but is also markedly higher in former smokers [34].
Methods
Study design
This was a prospective case-control study of patients
with neovascular AMD and healthy controls. The study
was approved by the Regional Committee of Ethics in
Research in Region Zealand (SJ-142). Verbal and written
informed consent was obtained from all participants
prior to inclusion. The described project adhered to the
tenets of the Declaration of Helsinki.
Participants
All participants were recruited from the Department of
Ophthalmology, Zealand University Hospital, Roskilde,
Denmark. Patients with neovascular AMD were recruited
from our retinal clinic. Healthy age-matched control indi-
viduals were relatives of the participating patients. This
was an intentional strategy to better match the control
group (lifestyle, diet, exposure, etc.). Since this was a
hypothesis-driven study, we were unable to perform
power-calculations, but based on previous experience with
flow cytometric studies of systemic leukocyte markers, we
aimed at recruiting at least 20 participants and stopped re-
cruitment after successfully analyzing 29 blood samples
from each group.
All participants were interviewed regarding medical
history and lifestyle. Smoking was considered active if
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the participants had smoked at any time within the last
year regardless of whether or not they had decided to
stop smoking [35]. Previous smokers and non-smokers
were both defined as not having smoked within the last
year, and previous and non-smokers were distinguished
by the latter having smoked less than 100 cigarettes (5
packs) during their entire lifetime [35]. Self-reported al-
cohol consumption was noted as units (=12 g ethanol)
per week. We calculated body mass index using weight
and height. Physical activity was assessed using a single
question for epidemiological studies which, has been
validated previously on patients with neovascular AMD
[36, 37].
We sampled fresh venous blood from the antecubital
vein in two tubes: one 5 mL ethylenediamine-tetraacetic
acid coagulant containing tube for flow cytometry and
one 3 mL lithium-heparin coated tube for determining
C-reactive protein (CRP) level.
Retinal diagnosis and eligibility
All participants had a comprehensive ocular examination
including measurement of best-corrected visual acuity,
slit-lamp examination, digital color fundus photography
(Carl Zeiss, Jena, Germany), Spectral-Domain Optical
Coherence Tomography, and fundus autofluorescence
imaging (Spectralis HRA-OCT, SLO Heidelberg Engin-
eering, Heidelberg, Germany). Retinal angiography using
fluorescein and indocyanine green were performed
where choroidal neovascularization was suspected. All
retinal diagnosis was confirmed by an experienced
ophthalmologist.
Healthy aged-matched controls individuals were only
considered for inclusion if they had normal maculae
with no more than 10 small drusen as defined in the
Clinical Age-Related Maculopathy Grading System
(CARMS) [38]. Any currently smoking participants were
not included. Participants with any infectious diseases
or immunological disorders were also not recruited, in-
cluding those in immune-modulating therapy for any
reason. We excluded any participant with a plasma
CRP-level > 15 mg/L to avoid participants with possible
ongoing infections [39]. To avoid interference with flow
cytometric analyses, we did not recruit patients with
neovascular AMD within 4 or 8 weeks respectively of
Ranibizumab or Aflibercept therapy or immediately
after retinal angiography [40].
Flow cytometry
All samples were analyzed within 4 h of phlebotomy.
We used the white blood cell count (Sysmex KX-21N™,
Sysmex Corporation, Kobe, Japan) to calculate a blood
volume, that would contain 5 × 105 leukocytes, which
we lysed in a 50 ml tube by adding red blood cell lysis
buffer (Nordic Biosite AB, Täby, Sweden), and waiting
10 min in the dark at room temperature. The cells were
washed three times; each time by centrifuging for 5 min
at 500G, decanting the supernatant, and re-suspending
in an isotonic buffer (IsoFlow Sheath Fluid, Beckman
Coulter Inc., Brea, CA, USA). For each blood sample, we
prepared four panels with monoclonal anti-human anti-
bodies for cell population gating and for the markers of
interest and two panels with fluorochrome-matched iso-
type controls: Phycoerythrin-Cyanine 7 (PC7) immuno-
globulin G (IgG) 1 (Cat. No.: 400,126; BioLegend, San
Diego, CA, USA), fluorescein isothiocyanate (FITC) IgG1
(Cat. No.: 400,108; BioLegend), phycoerythrin (PE) IgG1
(Cat. No.: 400,112; BioLegend), PC7 IgG2b (Cat. No.:
303,117; BioLegend), and PE IgG2b (Cat. No.: 400,212;
BioLegend). We incubated samples in darkness and at
room temperature, as recommended by the manufac-
turers. We then washed the cells, added 500 μL isotonic
buffer, and re-suspended. Stained cells (n = 100.000) were
analyzed using the flow cytometer BD FACS CANTO II
(BD Biosciences, FranklinLakes, NJ, USA) and Kaluza
Software (v. 1.5.20365.16139, Beckman Coulter Inc.,
Pasadena, CA,USA). All flow samples were analyzed using
the same settings on the flow cytometer.
On a forward/side scatter plot, we isolated granulocytes,
on which we used CD16 (Cat. No.: 360,712; BioLegend)
and CD14 (Cat. No.: 325,616; BioLegend) for identifying
neutrophils defined as CD14dimCD16+ (Fig. 1). On these
neutrophils, we studied cell markers of three important
functions of neutrophils: activation, adhesion, and reso-
lution of inflammation:
– Activation: CD63 (Cat. No.: 353,009; BioLegend)
and CD66b (Cat. No.: 305,103; BioLegend).
– Adhesion: CD11a (Cat. No.: 301,206; BioLegend),
CD11b (Cat. No.: 301,306; BioLegend), CD31 (Cat.
No.: 303,117; BioLegend), CD54 (Cat. No.: 533,107;
BioLegend), CD62L (Cat. No.: 304,821; BioLegend),
and CD162 (Cat. No.: 328,805; BioLegend).
– Resolution of inflammation: IL1-R2/CD121b (Cat.
No: LS-C139986–100; LifeSpan BioSciences Inc.,
Seattle, WA, USA), CXCR2/CD182 (Cat. No.:
320,706; BioLegend), CCR5/CD195 (Cat. No.:
359,107; BioLegend), and Duffy antigen/chemokine
receptor (DARC)/CD234 (Cat. No.: FAB4139P;
R&D Systems Inc., Minneapolis, MN, USA).
We determined the percentage of neutrophils that
were positive for the concerned marker. We gated the
positive cells and defined the median fluorescence inten-
sity (MFI).
Data analysis and statistics
First, we compared participant characteristics between
patients with neovascular AMD and the healthy control
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Fig. 1 Neutrophil gating and expression analysis. Here we analyze identify CD14dimCD16+ granulocytes (neutrophils) (Top) to study percentages
of CD62, CD11a, and CD11b positives and their expression level in terms of median fluorescence intensity
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individuals (demographics, co-morbidities, lifestyle factors,
and basic blood values such as white blood cell count,
neutrophil percentage and count, and plasma CRP). When
dealing with continuous data, we checked for normal dis-
tribution using histograms and the Kolmogorov-Smirnov
test. Where normal distribution was present, data was pre-
sented using mean and standard deviation (SD) and com-
pared using the independent samples t-test. Otherwise,
data was presented using median and interquartile range
(IQR) and compared using the Mann-Whitney U test. For
each category (activation, adhesion, and resolution of in-
flammation) of markers investigated, we compared the
percentage of positive neutrophils and their expression
level in terms of MFI. Acknowledging the potential influ-
ence of smoking, we evaluated whether healthy controls
differed in neutrophil markers between previous and non-
smokers. Since this was the case, we decided to repeat all
analyses on non-smokers only. All statistical analyses were
made in SPSS version 23 for Mac (IBM, Armonk, NY,
USA). P-values below 0.05 were interpret as sign of statis-
tical significance.
Results
We recruited a total of 61 individuals, of which 58 pro-
vided blood sample for our neutrophil study. One of the
healthy control individuals had a plasma CRP >15 mg/L
Table 1 Participant characteristics
Healthy controls (n = 28) Patients with neovascular AMD (n = 29) P-value
Demographics
Age, years, mean (SD) 77.2 (6.6) 79.4 (6.1) 0.192
Females, n (%) 12 (43) 20 (69) 0.047
Co-morbidities
Hypertension, n (%) 13 (46) 14 (48) 0.889
Hypercholesterolemia, n (%) 9 (32) 10 (34) 0.851
Cardiovascular diseases, n (%) 12 (43) 10 (34) 0.516
Type 2 diabetes, n (%) 2 (7) 2 (7) 1.000
Lifestyle factors
Body mass index, mean (SD) 25.8 (4.7) 26.7 (5.2) 0.506
Physically active, n (%) 6 (21) 9 (31) 0.410
Alcohol consumption, median (IQR) 7 (2 to 10) 3 (1 to 9) 0.126
Smoking status, n (%) 0.889
Previous smoker 15 (54) 15 (52)
Non-smoker 13 (46) 14 (48)
Blood measures
C-reactive protein, mg/L 0.029
< 2.9 mg/L 23 (82) 16 (55)
2.9–14.9 mg/L 5 (18) 13 (45)
White blood cell count, 109 cells/L, mean (SD) 5.9 (1.2) 6.4 (1.6) 0.212
Lymphocytes, mean (SD)
% 29 (8) 28 (9) 0.892
109 cells/L 1.7 (0.5) 1.8 (0.6) 0.654
Monocytes, mean (SD)
% 7 (2) 6 (3) 0.457
109 cells/L 0.4 (0.1) 0.4 (0.2) 0.678
Neutrophils, mean (SD)
% 64 (8) 65 (11) 0.618
109 cells/L 3.8 (1.0) 4.3 (1.5) 0.198
Neutrophils-to-lymphocytes, mean (SD) 2.52 (1.03) 2.80 (1.51) 0.422
Parametric continuous variables are presented using mean and standard deviation (SD) and tested using the independent samples t-test. Non-parametric continuous
variables are presented using median and interquartile range (IQR) and tested using the Mann-Whitney U test. Categorical variables are presented using numbers (n)
and percentages (%) and tested using the χ2-test, but due to very small numbers is co-morbidity of type 2 diabetes tested using the Fisher’s Exact test
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(22 mg/L) and was excluded from analyses. In total, 28
healthy control individuals and 29 patients with neovascu-
lar AMD were included for analyses. Mean age was 77.2
(SD: 6.6) years and 79.4 (SD: 6.1) years respectively for
patients and controls (P = 0.192; independent samples
t-test). Slightly more patients (n = 20, 69%) were female
when compared to controls (n = 12, 43%) (P = 0.047,
χ2-test). The patients and the control groups were gener-
ally similar in their co-morbidities and lifestyle character-
istics. White blood cell count, and leukocyte population
percentages and counts also did not differ significantly
between the groups. Increased plasma CRP was more
likely in patients with neovascular AMD (odds ratio
3.7, P = 0.033) (Table 1).
Activation
Activation markers did not differ significantly in per-
centage of positive neutrophils (Fig. 2). Expression level
of CD63 was also similar between groups. We observed
a trend towards higher expression level of CD66b in
patients with neovascular AMD, but this trend did not
reach a level of statistical significance. However, we re-
peated the analyses on non-smokers only and found
that among non-smokers, expression level of CD66b is
significantly higher in patients with neovascular AMD
when compared to healthy controls (P = 0.003; Mann-
Whitney U test) (Fig. 3).
Adhesion
Adhesion markers did not differ significantly in percent-
age of positive neutrophils (Fig. 2). Expression level on
the marker positive neutrophils were also similar be-
tween groups. Repeating the analyses on non-smokers
only showed that CD162 expression was slightly lower
in patients with neovascular AMD (P = 0.044; Mann-
Whitney U test) (Fig. 4).
Resolution of inflammation
Resolution of inflammation markers did not differ sig-
nificantly in percentage of positive neutrophils (Fig. 2).
Expression level on the marker positive neutrophils were
also similar for IL1-R2, CCR5, and DARC, but we ob-
served a non-significant trend towards lower CXCR2 on
neutrophils in patients with neovascular AMD. Repeat-
ing the analyses on non-smokers suggest that among
non-smokers, patients with neovascular AMD have sig-
nificantly lower expression of CXCR2 (P = 0.044; Mann-
Whitney U test) (Fig. 5).
Discussion
We find that among non-smokers, patients with neovas-
cular AMD had increased expression of the activity
marker CD66b, decreased expression of the adhesion
marker CD162, and lower expression of inflammation
marker CXCR2. Our results suggest that neutrophils
Fig. 2 Neutrophil expression of selected markers representing key steps of neutrophil conduct: adhesion, activation, and inflammation in patients
with neovascular AMD and healthy controls
Fig. 3 Expression of CD66b in patients with neovascular AMD and
healthy controls. Analysis performed for all participants and
for non-smokers
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may have specific components that play a role in neovas-
cular AMD.
Complement activation plays a key role in the patho-
genesis of AMD. Histopathological studies have found
complement components in eyes with drusen [41], which
are also reflected in altered levels of systemic complement
markers in patients with AMD [42, 43]. Interestingly,
complement activation induces CD66b overexpression
and drastically reduces the neutrophils’ phagocytic cap-
acity [25]. In light of these findings, we hypothesize that
CD66b overexpression on systemic neutrophils in patients
with neovascular AMD may reflect an increased systemic
level of complement components that in turn inhibit the
phagocytic capacity of the neutrophils. Consequently, we
speculate that the drusenoid macula may lack an appropri-
ate neutrophil response to the increased inflammatory and
angiogenic drive whereby CNV formation can proceed
unhampered.
Several studies suggest that AMD is associated with
immunosenescence and systemic presence of low-grade
inflammation [36, 44, 45]. We confirm this association
in CRP, which were higher in patients with neovascular
AMD. On neutrophils, such inflammatory environments
influence the expression of CD162 [46, 47]. CD162 is a
type 1 membrane protein that is constitutively expressed
on human neutrophils and able to interact with all 3
types of selectins: P-selectin on activated platelets and
endothelial cells, E-selectin on endothelial cells, and L-
selectin on leukocytes [26]. This interaction between
CD162 and its ligands is the first adhesion step and leads
to neutrophils rolling on the endothelium prior to adhe-
sion. Severe systemic inflammation in humans causes
rapid downregulation of CD162 on neutrophils [46]. In-
flammation of lesser degree have similar impact on
CD162, exemplified by one study of surgical stress after
cardiopulmonary bypass surgery [47]. Based on these
considerations, we speculate that low-grade inflamma-
tion in patients with AMD may cause CD162 downregu-
lation on neutrophils that in turn are less adherent.
CXCR2 is a chemokine receptor that regulates neutro-
phil recruitment in inflammatory contexts. Its function
in inflammation and tumor-related inflammatory activ-
ities is vital and CXCR2 modulation has been suggested
for treatment [48–50]. One study of CXCR2 deficient mice
demonstrated that CXCR2 plays an important role for
macrophage-dependent inflammatory response. In CXCR2
deficient mice, inflammatory responses were more exces-
sive, more macrophages were recruited to sites of inflam-
mation, and levels of anti- and pro-inflammatory cytokines
were shifted towards relatively more pro-inflammatory
levels [51]. Hence, CXCR2 controls the magnitude of
macrophage response in inflammation. We and other
groups have previously found that monocytes and mac-
rophages may play a key role in AMD and particularly
for CNV formation [22, 52–55]. Experimental laser-
induced lesions on mice retinae show that macrophages are
important for the CNV formation and systemic depletion
of macrophages lead to significantly lower lesion size [55].
In patients with neovascular AMD, monocyte levels are in-
creased in the first 30 days of new CNV diagnosis [22]. In
light of these findings, we hypothesize that a lower expres-
sion of CXCR2 and the aged and drusenoid macula may be
an ill-matched couple that orchestrates a more excessive
macrophage activity and pro-inflammatory environment
where CNV formation can occur. Interestingly, rheumatoid
arthritis which is associated with CXCR2 deficiency is also
associated with developing AMD later in life [56, 57].
Limitations of this study should be noted when inter-
preting its results. Importantly, this was an observa-
tional, case-control study, which can only associate but
not infer on causality. Thus, we cannot exclude that these
findings may also reflect a post-CNV state in the blood.
Fig. 4 Expression of CD162 in patients with neovascular AMD and
healthy controls. Analysis performed for all participants and
for non-smokers
Fig. 5 Expression of CXCR2 in patients with neovascular AMD
and healthy controls. Analysis performed for all participants and
for non-smokers
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We can only speculate on causality. However, findings of
previous studies suggesting that complement dysfunction,
low-grade inflammation, and CXCR2 deficiency all comes
prior to onset of AMD gives reasons to expect causality
[45, 57, 58]. The exploratory approach in the study and
the limited group sizes did not permit meaningful stratifi-
cations based on single nucleotide polymorphisms that
could be interesting, e.g. in the complement system
[58, 59] in light of our findings on CD66b. Our study
design cannot determine whether the findings reflect
immunological dysfunction that are seen in a broad
range of retinal diseases or mechanisms that specifically
lead to AMD. Future studies need to investigate other
retinal and ophthalmological diseases to clarify such
aspects.
Conclusions
In summary, we find that in non-smokers, patients with
neovascular AMD present with neutrophils that have
increased expression of the activity marker CD66b, de-
creased expression of the adhesion marker CD162, and
lower expression of the resolution of inflammation marker
CXCR2. Circulating neutrophils may play a role for neo-
vascular AMD and experimental studies are warranted to
fully clarify how and when these neutrophil dysfunctions
contribute to disease development.
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